AbbVie (NYSE: ABBV) has announced the progression of lutikizumab to Phase III clinical trials following the IL1α/1β antagonist’s successful performance in a mid-stage trial for patients with moderate-to-severe hidradenitis suppurativa (HS) who had failed anti-TNF therapy. The study successfully met its primary endpoint, demonstrating a 35% higher clinical response rate compared to placebo.
As detailed in the press release, the biologic showed a favorable safety profile, being generally well-tolerated with no dose-dependent trends observed in adverse events or infections, indicating its potential as a treatment for HS.- Flcube.com
